

Company Presentation

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
VBL-Therapeutics (NASDAQ: VBLT), is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. Our lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma.
- **Business Strategy**
We expect an interim analysis in our Phase 3 study in mid-2017 and top-line data in early 2018. We intend to take VB-111 to commercialization through rGBM and advance its development for ovarian cancer. We intend establish collaboration/s with strategic-partner/s to advance VB-111 to additional cancer indications. In addition, we have a pipeline of assets in the immunology/oncology space that we can monetize/partner.
- **Core Technology**
VBL has pioneered the Vascular-Targeting-System (VTS)TM, a first-in-class gene-therapy platform technology which enables systemic administration of genes to destroy or promote angiogenic blood vessels. VBL has also pioneered the Lecinoxoids platform of anti-inflammatory small-molecules and is developing MOSPD2-targeting candidates for Immuno/Oncology applications.
- **Product Profile/Pipeline**
Our lead oncology product candidate VB-111, is a novel, targeted biologic agent. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. VB-111 has Fast-Track status and Orphan designation in US and EU.
- **What's Next?**
We completed recruitment for the pivotal study of VB-111 in rGBM and expect to have an interim analysis in the third quarter of 2017 and top-line data in early 2018. VBL has strong cash balance to execute its programs into 2019 beyond the readout of this singly-needed pivotal trial.